Benefits Simple dosing Mild titration schedule Good for long-term glucose management Suitable for patients who prefer minimal dose changes Considerations Not approved for weight loss Weight reduction is typically more modest than with semaglutide or tirzepatide May cause nausea during dose increases As with Ozempic, some pharmacies charge more than others for Trulicity
Overall, tirzepatides dual agonism of GLP1 and GIP receptors appears to provide encouraging cardiovascular benefits beyond glycemic control, offering a potential new therapeutic option for treating cardiovascular diseases and heart failure
Visits are completed through a secure platform, allowing a licensed healthcare provider to review health history and determine whether treatment options may be appropriate
Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity
If plan sponsors decide to cover these medications for weight loss, they should consider implementing a broader health and wellness strategy, one that includes diet exercise, and behavior changes for best long-term results